Kathy Nicholls

8PUBLICATIONS
81CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsMetabolic medicineAudiologyForest health and pathologyTime-series analysis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 17, 2026
Scaling up Genomics: A Mainstream Model of Care in Nephrology.

|Jan 10, 2026
Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension.

Peter Nordbeck, Ozlem Goker-Alpan, John A Bernat

|May 24, 2024
The Effect of Fabry Disease Therapy on Bone Mineral Density.

Tess Aitken, Mark K Tiong, Andrew S Talbot

|Jan 12, 2024
Fabry-specific treatment in Australia: time to align eligibility criteria with international best practices.

Kathleen Nicholls, Charles Denaro, Michel Tchan

|Aug 26, 2022
Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease.

Markus Cybulla, Kathleen Nicholls, Sandro Feriozzi

|Nov 22, 2019
Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis.

Uma Ramaswami, Michael Beck, Derralynn Hughes

Pageof 2

Frequent Collaborators

3 joint publications

Michael L West

2 joint publications

Anna Leaver

2 joint publications

John Whitlam

2 joint publications

Simon Bodek